Survey: Doctors Share Interest in Drug Costs but Fail to Monitor for Adherence
While there’s plenty of evidence and feedback on how consumers feel about the price of drugs, there has been less detail made public about how physicians view these soaring costs and what they consider their role in the supply chain to be. However, a recent OptimizeRX survey that polled more than 600 providers found drug costs to be top of mind for doctors in the same way they are for consumers.
List of the Most Expensive Drugs Sees Continued Increases, New Meds Added
When it comes to most consumer goods, the flashy new items are the ones that fetch the highest dollar. Meanwhile, the price of the ordinary, decades-old models without the latest bells and whistles tend to remain relatively flat and unchanged. As an example of this pattern, you can look no further than vacuums. Unfortunately, outpatient drugs aren’t like vacuums.
Exclusive Rights for Drugs Leading to Skyrocketing Costs
There was a time when hospitals stocked Intensive Care Units with vasopressin like it was a common antibiotic. The inexpensive price tag supported buying the drug in bulk, and its use to fight sepsis and restore the flow of blood to vital organs like the brain made it an essential component of any crash cart.
Podcast: NC Senator Ralph Hise Talks Surprise Billing and the Proposal to Stop it
When it comes to consumerism in health care, one of the most important things we constantly urge for our readers is to be a knowledgeable consumer. That means doing the preparation in advance to know what type of out-of-pocket costs you might expect so that you can best prepare for your financial responsibility as a patient.
CDC: Americans Asking for Cheaper Drugs, Skipping Doses Due to Inflated Costs
While the toll taken on Americans by rising drug costs shouldn’t come as much of a surprise, a new report issued by the Centers for Disease Control and Prevention (CDC) has shed light on the depths of that impact.
PBMs Set to Defend Position as Senate Continues Drug Cost Probe
Just weeks after leadership from the world’s most influential pharmaceutical companies told the Senate Finance Committee that pharmacy benefit managers (PBMs) were to blame for high drug costs, an assortment of PBMs will appear before the same committee on April 9.